Trial Profile
COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Zorecimeran (Primary) ; Hepatitis A vaccine; Pneumococcal vaccine
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors CureVac
- 21 Sep 2023 Primary and secondary outcome measures with time frame amended.
- 09 Mar 2022 Status changed from active, no longer recruiting to completed.
- 25 Nov 2021 Planned End Date changed from 9 Nov 2021 to 18 Feb 2022.